260 related articles for article (PubMed ID: 34733275)
1. Radiogenomics Map Reveals the Landscape of m6A Methylation Modification Pattern in Bladder Cancer.
Ye F; Hu Y; Gao J; Liang Y; Liu Y; Ou Y; Cheng Z; Jiang H
Front Immunol; 2021; 12():722642. PubMed ID: 34733275
[TBL] [Abstract][Full Text] [Related]
2. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
3. Characterization of m
Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
Front Immunol; 2021; 12():782551. PubMed ID: 34975871
[TBL] [Abstract][Full Text] [Related]
4. The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer.
Wang J; Lin H; Zhou M; Xiang Q; Deng Y; Luo L; Liu Y; Zhu Z; Zhao Z
Future Oncol; 2020 Oct; 16(30):2421-2432. PubMed ID: 32687727
[No Abstract] [Full Text] [Related]
5. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
Liu Z; Zhong J; Zeng J; Duan X; Lu J; Sun X; Liu Q; Liang Y; Lin Z; Zhong W; Wu W; Cai C; Zeng G
Front Immunol; 2021; 12():735170. PubMed ID: 34531875
[TBL] [Abstract][Full Text] [Related]
7. Identification of prognostic m6A modification patterns and score system in melanoma patients.
Wang F; Chen P; Ouyang S; Xiong K; Liu Z; Wang Y
Medicine (Baltimore); 2024 Apr; 103(17):e37950. PubMed ID: 38669381
[TBL] [Abstract][Full Text] [Related]
8. m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma.
Huang ZD; Lin LL; Liu ZZ; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():765723. PubMed ID: 35003079
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
10. m6A regulator-mediated RNA methylation modification patterns and immune microenvironment infiltration characterization in severe asthma.
Sun D; Yang H; Fan L; Shen F; Wang Z
J Cell Mol Med; 2021 Nov; 25(21):10236-10247. PubMed ID: 34647423
[TBL] [Abstract][Full Text] [Related]
11. A five-gene signature derived from m6A regulators to improve prognosis prediction of neuroblastoma.
Wang Z; Cheng H; Xu H; Yu X; Sui D
Cancer Biomark; 2020; 28(3):275-284. PubMed ID: 32176634
[TBL] [Abstract][Full Text] [Related]
12. m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer.
Chen M; Nie ZY; Wen XH; Gao YH; Cao H; Zhang SF
Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31808521
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
Liu J; Wang J; Wu M; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
Front Med (Lausanne); 2021; 8():757432. PubMed ID: 35004726
[No Abstract] [Full Text] [Related]
14. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.
Du J; Ji H; Ma S; Jin J; Mi S; Hou K; Dong J; Wang F; Zhang C; Li Y; Hu S
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33594424
[TBL] [Abstract][Full Text] [Related]
15. Multi-omics comprehensive analysis reveals the predictive value of N6-methyladenosine- related genes in prognosis and immune escape of bladder cancer.
Liu Y; Pang Z; Wang J; Wang J; Ji B; Xu Y; He J; Zhang L; Han Y; Shen L; Xu W; Ren M
Cancer Biomark; 2024; 40(1):79-94. PubMed ID: 38517777
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types.
Shen S; Zhang R; Jiang Y; Li Y; Lin L; Liu Z; Zhao Y; Shen H; Hu Z; Wei Y; Chen F
Mol Cancer; 2021 Apr; 20(1):67. PubMed ID: 33849552
[TBL] [Abstract][Full Text] [Related]
17. N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma.
Xu H; Yin L; Xu Q; Xiang J; Xu R
Cancer Cell Int; 2022 May; 22(1):199. PubMed ID: 35606813
[TBL] [Abstract][Full Text] [Related]
18. The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.
Shen X; Hu B; Xu J; Qin W; Fu Y; Wang S; Dong Q; Qin L
Cancer Biol Med; 2020 Nov; 17(4):937-952. PubMed ID: 33299645
[TBL] [Abstract][Full Text] [Related]
19. m6A Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment.
Zhang W; Xiao P; Tang J; Wang R; Wang X; Wang F; Ruan J; Yu S; Tang J; Huang R; Zhao X
Front Immunol; 2022; 13():888650. PubMed ID: 35572541
[TBL] [Abstract][Full Text] [Related]
20. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
